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BAP1 deficiency causes loss of melanocytic cell
identity in uveal melanoma
Katie A Matatall1, Olga A Agapova1, Michael D Onken1, Lori A Worley1, Anne M Bowcock2 and J William Harbour1,3,4*
Abstract
Background: Uveal melanoma is a highly aggressive cancer with a strong propensity for metastasis, yet little is
known about the biological mechanisms underlying this metastatic potential. We recently showed that most
metastasizing uveal melanomas, which exhibit a class 2 gene expression profile, contain inactivating mutations in
the tumor suppressor BAP1. The aim of this study was to investigate the role of BAP1 in uveal melanoma
progression.
Methods: Uveal melanoma cells were studied following RNAi-mediated depletion of BAP1 using proliferation,
BrdU incorporation, flow cytometry, migration, invasion, differentiation and clonogenic assays, as well as in vivo
tumorigenicity experiments in NOD-SCID-Gamma mice.
Results: Depletion of BAP1 in uveal melanoma cells resulted in a loss of differentiation and gain of stem-like
properties, including expression of stem cell markers, increased capacity for self-replication, and enhanced ability to
grow in stem cell conditions. BAP1 depletion did not result in increased proliferation, migration, invasion or
tumorigenicity.
Conclusions: BAP1 appears to function in the uveal melanocyte lineage primarily as a regulator of differentiation,
with cells deficient for BAP1 exhibiting stem-like qualities. It will be important to elucidate how this effect of BAP1
loss promotes metastasis and how to reverse this effect therapeutically.
Keywords: BAP1, Uveal melanoma, Differentiation, Stem cell, Metastasis, Tumor suppressor
Background
Uveal melanoma is a highly aggressive cancer that
arises from melanocytes within the uveal tract of the
eye. Uveal melanomas can be classified according to
their transcriptomic signature into two prognostically
significant subtypes. Class 1 uveal melanomas are less
aggressive and rarely metastasize, whereas class 2 uveal
melanomas are highly aggressive and commonly give
rise to fatal metastatic disease [1,2]. We recently showed
that inactivating mutations in the tumor suppressor BAP1
occur almost exclusively in class 2 tumors and are strongly
associated with metastasis, suggesting that BAP1 may
function as a metastasis suppressor in uveal melanoma
[3]. One patient in this report carried a germline BAP1
mutation, indicating that BAP1 mutations can give rise
to a familial cancer syndrome. Since this report, som-
atic and germline BAP1 mutations have been identified
in a variety of other tumors, including mesothelioma,
cutaneous melanoma, atypical cutaneous melanocytic
tumors, lung adenocarcinoma, meningioma and renal
cell carcinoma [4-9].
BAP1 (BRCA1-associated protein-1) is an ubiquitin
carboxy-terminal hydrolase that was identified in a
screen for proteins that interact with BRCA1 [10]. It
was initially found to be mutated in a few breast and
lung cancer cell lines, where it exhibited tumor suppressor
activity upon re-introduction [10]. BAP1 has been
suggested to function in several pathways, including
DNA damage repair, cell proliferation and develop-
ment [11-14].
In Drosophila the BAP1 homolog Calypso is a compo-
nent of the PR-DUB Polycomb repressive complex, and
its loss results in a developmental phenotype characterized
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by deregulated HOX gene expression [14]. This study
showed that both Calypso and human BAP1 catalyze
the removal of monoubiquitin moieties from histone
H2A when in the presence of Asx or ASXL1, res-
pectively. This activity of BAP1 opposes the H2A
ubiquitinating activity of the PRC1 complex, which
contains BMI1. Interestingly BMI1 is an oncogene in-
volved in stem cell maintenance, and its over-expres-
sion leads to a loss of cell identity in multiple cancers
[15]. We recently showed that BAP1 loss causes in-
creased histone H2A ubiquitination in melanoma cells
and melanocytes, and this hyperubiquitination was
reversed by treatment with HDAC inhibitors, which
inhibit BMI1 [16].
Another recent study found that BAP1 loss leads to a
myelodysplastic syndrome (MDS) in mouse [17]. They
found that the predominant BAP1-interacting proteins
in the hematopoietic lineage are HCF-1, OGT, ASXL1/2,
and FOXK1/2, which is consistent with other studies
[12-14,18]. In contrast to the findings in Drosophila,
however, BAP1 loss in mouse did not effect HOX gene
expression, suggesting that BAP1 may have divergent
roles across species.
Despite the recently renewed interest in BAP1, the
precise cellular impact of BAP1 loss during tumorigen-
esis remains unclear. In this study, we wished to deter-
mine the function of BAP1 in uveal melanoma, where
BAP1 loss appears to play a specific role in tumor
progression and acquisition of metastatic capacity. Our
findings suggest that a major role for BAP1 in this set-
ting is to regulate transcriptional programs involved in
maintaining a differentiated melanocytic phenotype and
that loss of BAP1 triggers a loss of cell identity charac-
terized by a primitive, stem-like phenotype.
Methods
Tissue culture
Three uveal melanoma cell lines OCM1A, 92.1, and
Mel290 (kindly provided by Drs. J. Kan-Mitchell, M.
Jager and B. Ksander, respectively) were used in this
study. All three cell lines are wildtype for BAP1. 92.1
cells contain a GNAQQ209L mutation, OCM1A cells con-
tain a BRAFV600E mutation, and Mel290 cell lines are
wildtype for both GNAQ and BRAF; all of the cell lines
are wildtype for GNA11 [19]. These cell lines are well-
established tools in the field of uveal melanoma research
and their mutational status is representative of the spec-
trum seen in uveal melanoma. Due to the low frequency
of BRAF mutations in uveal melanoma, OCM1A cells
may not be representative of the vast majority of primary
uveal melanomas. All uveal melanoma cell lines were
grown in RPMI-1640 supplemented with 10% FBS, L-
glutamine, and antibiotics at 5% CO2. Primary uveal
melanoma samples were collected at the time of
enucleation and informed consent was obtained for
each patient. All samples were confirmed to be uveal
melanomas by pathologic evaluation and melanoma
cells were isolated and grown as previously described
[20]. Primary uveal melanoma cells were grown on
collagen-covered tissue culture plates in 5% CO2 and 4%
O2 in MDMF medium which consists of HAM’s F12
(Lonza, Walkersville MD, USA) supplemented with
1 mg/ml BSA (Sigma-Aldrich, St Louis MO, USA),
2 mM L-glutamine (Lonza), 1X SITE (Sigma-Aldrich),
1x B27 (Gibco, Carlsbad CA, USA), 20 ng/ml bFGF
(PeproTech Inc, Rocky Hill NJ, USA), 50 μg/ml Gen-
tamicin (Sigma-Aldrich) and 2.5 μg/ml AmphotericinB
(Sigma-Aldrich). Primary melanocytes were isolated from
unaffected choroid, obtained at the time of enucleation.
Normal uveal melanocytes were handled in the same
manner as primary uveal melanoma cells except they
were maintained in OPTI-MEM medium supplemented
with 10 ng/ml bFGF (PeproTech Inc, Rocky Hill NJ,
USA), 10 ng/ml PMA (Sigma-Aldrich), 0.1 mM IBMX
(Sigma-Aldrich), 1 ng/ml Heparin (Sigma-Aldrich), 50 μg/
ml Gentamicin (Sigma-Aldrich) and 2.5 μg/ml Ampho-
tericinB (Sigma-Aldrich).
BAP1 depletion
Transient knockdown was carried out using BAP1 or
control siRNA (Ambion, Austin TX, USA) in 92.1 and
Mel290 uveal melanoma cell lines as previously de-
scribed [3]. Lentiviral-based short hairpin RNA (shRNA)
was used to deplete BAP1 or control gene, GFP from
cultured cells for long-term experiments. Lentiviral
pLKO.1 shRNA vectors for GFP (clonetechGfp-438s1c1)
and BAP1 (NM_004656.2-2658s1c1 and NM_004656.2-
321s1c1) developed by the RNAi Consortium (TRC)]
were purchased from the Children's Discovery Institute/
Genome Sequencing Center at Washington University
in St. Louis. Viral production and infections were carried
out according to The RNAi Consortium recommen-
dations (Broad Institute). Lentiviruses were packaged in
293FT cells (Invitrogen, Carlsbad CA, USA) after cotrans-
fection of the shRNA plasmids with pCMV-dR8.2 dvpr
and pCMV-VSV-G lentiviral plasmids (Addgene plasmids
#8454 and #8455, deposited by Bob Weinberg, [21])
using TransIT-LT1 (Mirus, Madison WI, USA). Cells
were infected for 24 hours with lentiviral supernatants
in the presence of 5 μg/ml protamine sulfate. Puro-
mycin (3 μg/mL) was added to the cells at 24 hours
postinfection for selection as previously described [16].
With the exception of primary class 1 tumor cells, which
were under selection for one week, all infected cells
were selected for at least two weeks before use in ex-
periments and were maintained under selection for up
to four weeks (referred to as BAP1-deficient or control
stable cells).
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Growth assays
MTS assays were performed using CellTiter 96 AQueous
Assay reagent (Promega, Madison WI, USA) according
to manufacturer's instructions. Bromodeoxyuridine (BrdU)
incorporation assays were performed in 96-well plates
and colorimetric changes were measured at 370 nm
using a Microplate spectrophotometer (SpectraMAX 190;
Molecular Devices) as previously described [16]. Flow
cytometry was performed using a standard propidium
iodide staining protocol as previously described [22]
using a FACScan analyzer (BD Biosciences, San Diego
CA, USA). The percentage of cells in each phase was
determined using FlowJo software. Assays assessing the
growth of cells in stem cell conditions were performed
by plating 1000 or 2000 cells/well (OCM1A or 92.1,
respectively) in 24-well ultra-low attachment plates
containing stem cell medium, MDMF. After 5 or 7 days
(OCM1A or 92.1, respectively) images were taken at
40X magnification and colony size was measured using
ImageJ software. For clonogenic assays using OCM1A
and 92.1 cells, flow cytometry (MoFlo; Cytomation)
was used to seed one viable cell per well in ultra-low
attachment 96-well plates containing MDMF medium
as previously described [23]. Cell morphology of pri-
mary uveal melanocytes was assessed by phase contrast
microscopy as previously described [16].
For HDAC inhibitor studies 0.5 mM, 1.0 mM or
2.0 mM valproic acid (Sigma-Aldrich) dissolved in water
was added to BAP1-deficient or control cells for 72 hrs
before RNA was isolated.
Tumorigenicity assays
Soft agar assays were performed as previously described
[23]. Plates were stained with MTT after 2 weeks and
images were taken 6.7X using a dissecting scope and
colonies were counted using ImageJ software. Scratch
assays were carried out by plating 2x105 cells/well in 12
well plates. Before scratching with a P200 tip, cells were
treated with 5 μg/ml mitomycin C for 2 hrs at 37°C and
washed with PBS. Two 100X images were taken per well
and a total of three wells were imaged per condition for
each experiment. Images were taken at Day 0, 1 and 2 and
closure of the scratch was measured using ImageJ. Time-
lapse microscopy was performed by plating cells on colla-
gen coated 8-well chamber slides (Thermo Fisher Scientific,
Rochester NY, USA) at a concentration of 1000 cells/well.
The cells were allowed to attach overnight at 37°C and then
imaged using an inverted Nikon Eclipse Ti at 200X every
15 minutes for 16 hrs. Cells were manually tracked using
NIS Elements software (Nikon, Melville NY, USA).
Immunoprecipitations and western blots
Cell lysates for both westerns and immunoprecipitations
(IPs) were prepared by resuspending cell pellets in lysis
buffer, which consists of 50 mM Hepes pH7.2, 400 mM
NaCl, 0.1% NP-40, 0.5 mM EDTA pH8, 2.5 mM DTT,
plus protease and phosphatase inhibitors. Samples were
then incubated on ice for 10mins before a 10 sec, low-
power sonication. After which, samples were spun down
to remove cellular debris and supernatants were then
used for either westerns or IPs. For westerns 20 μg of
protein was loaded for each sample. IPs were performed
using combined lysates from OCM1A, 92.1, and Mel290
uveal melanoma cell lines. After sonication, lysates were
pre-cleared with ProteinG Sepharose beads (Sigma-Al-
drich) for 1 hr and incubated overnight at 4°C with 5 μg
of the indicated antibodies. After incubation for 1 hr
with fresh sepharose beads, samples were spun down
and beads were washed twice with lysis buffer. Proteins
were eluted by boiling the samples with 6X SDS loading
buffer for 5 mins. IP supernatants (the supernatant re-
moved from the tube after the initial IP pulldown) were
kept for western blot analysis and are referred to as
cleared lysates. IP samples and cleared lysates were
subjected to SDS-PAGE followed by western blotting for
the indicated antibodies. Densitometry was performed
on western blots using ImageJ software. Antibodies used
for IP and western blot were BAP1 (Santa Cruz, Santa
Cruz CA, USA), HCF-1 (Bethyl Laboratories, Montgom-
ery TX, USA), α-tubulin (Sigma-Aldrich), and control
antibodies rabbit IgG and mouse IgG (Santa Cruz).
RNA analysis
For primary melanocytes and tumor samples total RNA
was extracted with TRIzol (Invitrogen) according to the
manufacturer’s protocol and purified by ammonium
acetate precipitation. RNA was extracted from cell lines
using an RNeasy Kit (Qiagen) according to the manu-
facturer’s protocol. The RNA was DNase treated and
reverse transcribed using iScript cDNA Synthesis Kit
(Bio Rad, Hercules CA, USA). Primary melanocyte and
tumor sample RNA was preamplified for 14 cycles with
pooled primers according to the manufacturer's protocol
using TaqMan PreAmp Master Mix (Applied Biosystems,
Foster City CA, USA). mRNA levels were measured by
qPCR using iTaq SYBR Green Supermix (Bio Rad) as
previously described [3]. UBC was used as an endogen-
ous control. Primer sequences are listed in Additional
file 1.
Gene expression profiling
Gene expression profiling (GEP) was performed on two
independent sets of uveal melanoma cell lines (OCM1A,
92.1 and Mel290), each expressing either GFP or BAP1
shRNA for four weeks (12 samples total). Total RNA
was isolated using the RNeasy kit (Qiagen). RNA quality
was assessed on the Bioanalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA). Samples were subjected to
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gene expression profiling using the HumanHT-12 v4
Expression BeadChip (Illumina, San Diego, CA, USA).
Raw expression data were subjected to cubic spline nor-
malization in GenomeStudio (version 2011.1). ANOVA
and hierarchical clustering were performed with Partek
Genomics Suite (version 6.6) using a significance of P <
0.01 as a threshold for gene inclusion. Significance
Analysis of Microarrays (SAM), Version 4.0 [24] was
used to generate a ranked gene list, and a threshold of
q < 10% was then used to select the most highly signifi-
cant genes that were up or down regulated after BAP1
loss. This list was used to determine the most highly
represented gene ontology categories and genes from
this list were selected for validation by qPCR. A pre-
ranked file was generated from the SAM output data
and run through Gene Set Enrichment Analysis (GSEA),
version 2.0.4 [25,26] to identify significantly enriched
gene sets. Gene expression data have been deposited in
the NCBI Gene Expression Omnibus and are accessible
through GEO Series accession number GSE48863.
SNP arrays
Three uveal melanoma cell lines (OCM1A, 92.1, and
Mel290) expressing either GFP or BAP1 shRNA for four
weeks were subjected to single nucleotide polymorphism
(SNP) arrays using Affymetrix Human Genome-Wide
SNP 6.0 array (Affymetrix, Santa Clara, CA, USA). DNA
was isolated using a DNeasy kit (Qiagen). Copy number
and allele ratios were calculated using Partek Genomics
Suite (version 6.6). For paired analyses, cell lines express-
ing GFP shRNA were used as baselines; for unpaired
analyses, the Partek distributed baseline was used as a
reference. Hidden Markov Model genomic smoothing
was used to identify significant regions of amplification
and deletion in samples expressing BAP1 shRNA com-
pared to control samples.
Animal studies
Animal experiments were approved by the Washington
University in St. Louis Animal Studies Committee. 5–
8 week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX [non-
obese diabetic severe-combined immunodeficient gamma
(NSG)] males (Jackson Laboratory) were injected sub-
cutaneously into the flank with 500 OCM1A or 1000 92.1
cells in 50 μl Cultrex (Trevigen, Gaithersburg MD, USA).
Tumor size was monitored once a week and the mice
were euthanized after 34 (OCM1A) or 64 (92.1) days at
which time tumors were collected and measured. Vol-
ume of each tumor was calculated using the ellipsoid
volume formula (π xyz/6 mm3). Tumors were collected
in TRIzol at time of necropsy for RNA isolation. For
different experiments 10,000 92.1 cells or 500,000
OCM1A were injected into the tail vein of 5–8 weeks
old NSG males or females. Mice were monitored and
euthanized after 29 or 44 days respectively. Organs were
collected and fixed in 10% formalin. Fixed liver and
lungs were cut into 5 mm thick pieces, dehydrated and
embedded in paraffin as a single block. Four micron
sections were cut and stained with H&E. Overlapping
images of the sections were taken at 20X and merged
to one image using AdobePhotoshop CS4. Total liver
or lung area, and metastasis area were measured using
ImageJ 1.45 s for calculation of % of metastasis.
Results
BAP1 loss causes transient cell cycle inhibition
To study the effects of BAP1 loss in uveal melanoma
cells, we initially used siRNA to achieve at least an ~
80% depletion of BAP1 protein levels (Figure 1a). This
resulted in a 20-40% reduction in cell cycle progression,
measured by BrdU incorporation in two different uveal
melanoma cell lines (92.1 and Mel290), which persisted
through the four day experiment (Figure 1b-c). This obser-
vation is consistent with previous findings in MCF10A
Figure 1 Transient loss of BAP1 causes a decrease in
proliferation in uveal melanoma cells. (a) Western blot of two
uveal melanoma cell lines, 92.1 and Mel290, showing the levels of
BAP1 after transient knockdown of BAP1 with two independent
siRNAs compared to control siRNA. α-tubulin was used as a loading
control (b-c) Cell proliferation of the indicated melanoma cell lines
transfected with BAP1 (grey line) or control (black line) siRNA.
Proliferation was measured by BrdU incorporation and shown as
fold change compared to Day 1 (b) 92.1 cells (c) Mel290 cells.
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breast epithelial cells and HeLa cervical carcinoma cells
[11,13,27]. To study longer-term effects of BAP1 loss,
we used short-hairpin RNA (shRNA) expressed from
lentiviral vectors, which consistently achieved 70-90%
depletion of BAP1 protein levels in three different uveal
melanoma cell lines (OCM1A and 92.1, and Mel290)
(Figure 2a). BAP1-depleted cells were then compared
to those infected with control lentivirus expressing
shRNA directed against GFP. Interestingly, there was
no substantial difference in cell viability, BrdU incorp-
oration or cell cycle profile between BAP1-deficient
and control cells after stable expression of the shRNA
constructs for at least 14 days (Figure 2b-d), indicating
that the initial cell cycle inhibition caused by BAP1 de-
pletion was transient.
Effects of BAP1 loss on tumorigenicity
The uveal melanoma cells stably expressing shRNA
against BAP1 and control shRNA against GFP were
compared using in vitro and in vivo assays of tumori-
genicity. Using scratch assays as a measure of cell motility,
BAP1-deficient uveal melanoma cells were less motile
than control cells (Figure 3a). Prompted by this unex-
pected finding, we performed time-lapse microphotog-
raphy and confirmed that BAP1-deficient cells showed
less overall movement than control cells (Figure 3b).
Similarly, BAP1-deficient uveal melanoma cells were
less capable than control cells of anchorage independ-
ent growth in soft agar assays (Figure 3c).
To assess the ability to form tumors in vivo, we created
flank tumors in NOD-SCID gamma mice using BAP1-
deficient versus control uveal melanoma cells. Surpris-
ingly, the BAP1-deficient tumors were smaller than
control tumors (Figure 4a). We confirmed that BAP1
was still depleted in these tumors by isolating RNA at
the time of necropsy and performing qPCR (Figure 4b).
To assess metastatic capacity, we then performed tail
vein injections of BAP1-deficient and control uveal
melanoma cells in the same mouse strain, and the
BAP1-deficient cells formed fewer metastases in the
liver and lungs compared to control cells (Figure 4c-e
and Additional file 2).
Global genomic effects of BAP1 loss
Given these unexpected findings, we wished to gain in-
sights into the role of BAP1 loss in uveal melanoma
progression by analyzing the changes in global gene ex-
pression associated with BAP1 depletion. We analyzed
the transcriptome of all three uveal melanoma cell lines
using Illumina BeadArrays at four weeks after stable
shRNA expression (Figure 5a). In order to identify the
most significantly altered genes, we used Significance
Figure 2 Stable loss of BAP1 does not promote cell proliferation in uveal melanoma cells. (a) Western blot showing the levels of BAP1
after stable knockdown of BAP1 with two independent lentiviral shRNA constructs in three uveal melanoma cell lines, OCM1A, 92.1, and Mel290.
α-tubulin was used as a loading control (b) Cell viability and proliferation of the indicated BAP1-deficient or control stable cells (Left panel) cell
viability measured by MTS assay and shown as fold change over day 0 for each stable cell line (Right panel) cell proliferation measured by BrdU
incorporation after 24 hrs (c-d) Cell cycle analysis of the indicated cell lines using flow cytometry on propidium iodide stained cells; x-axis
represents DNA content and y-axis represents cell number (c) 92.1 stable cells (d) OCM1A stable cells.
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Analysis of Microarrays (SAM) with a false discovery
rate cut-off of 10% and found 77 genes that were up-
regulated (16 of these were pseudogenes or uncharac-
terized loci), and 6 genes that were down-regulated by
BAP1 depletion (Additional file 3 and Additional file
4). The finding that more genes were up-regulated than
down-regulated by depletion of BAP1 is consistent with
its known role in transcriptional repression as part of
the Polycomb PR-DUB complex [14]. The most common
Gene Ontology categories included RNA metabolism
(14 genes, including 10 specifically involved in RNA
splicing), developmental processes (11 genes), ubiquitin
system (8 genes), apoptosis (4 genes), cell cycle (4 genes),
and epigenetic regulation (4 genes) (Figure 5b). Among
the genes involved in the ubiquitin system, three were
involved not with ubiquitin-associated protein degrad-
ation, but with substrate deubiquitination.
The set of differentially expressed genes was further
analyzed for functional significance using Gene Set En-
richment Analysis. Genes with altered expression upon
BAP1 depletion exhibited significant (p < 0.005) enrich-
ment in gene sets involved in proliferation/cell cycle
control (14 gene sets), development and stem cell bio-
logy (9 gene sets), RNA splicing (6 gene sets), DNA
damage repair (6 gene sets), metastasis (6 gene sets),
epigenetic regulation (5 gene sets), amino acid metabol-
ism (5 gene sets), the BRCA1/2 pathway (3 gene sets)
and mitochondrial activity (3 gene sets) (Figure 5c and
Additional file 5, Additional file 6 and Additional file
7). The metastasis gene sets included genes that were
up-regulated in metastasizing melanoma, as well as
prostate, lung, and pancreatic cancer.
There were 3 BRCA1/2 pathway gene sets indentified,
and among the 6 DNA damage repair gene sets, 3 were
related to telomere maintenance. Since BRCA pathway
deregulation and telomere dysfunction are both associ-
ated with amplifications and deletions in cancer cells
[28,29], we wished to determine whether BAP1 depletion
might result in such large-scale chromosomal gains and
losses in uveal melanoma cells. However, Affymetrix 6.0
SNP arrays showed no differences in chromosome num-
ber between BAP1-deficient versus control cells for any
of the three uveal melanoma cell lines after 4 weeks of
BAP1 depletion. (Additional file 8).
Figure 3 Loss of BAP1 does not promote in vitro tumorigenicity in uveal melanoma cells. (a) Wound healing assays were performed on
the indicated BAP1-deficient or control stable cells. (Left panel) representative pictures of Mel290 cells after stable knockdown at Day 0
(time of scratch) and Day 1. (Right panel) quantification of wound healing assays shown as percent of total area of the initial wound (b)
BAP1-deficient or control Mel290 stable cells were monitored every 15mins for 16 hrs using live cell imaging. Individual cells were manually
tracked and the average distance per frame (left panel) and the total distance traveled (right panel) were calculated (c) Soft agar assays
performed on BAP1-deficient or control OCM1A stable cells after one week of growth. (Left panel) representative pictures of soft agar plates
stained with crystal violet. (Right panel) quantification of the number of small and large colonies per plate determined using ImageJ
software. * denotes P < 0.05 and ** denotes P < 0.01 based on Student’s t-test.
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BAP1 loss induces a stem-like cellular phenotype in
melanoma cells
Prompted by these transcriptomic findings, we wished
to explore further the possibility that BAP1 inhibits
metastasis of uveal melanoma cells by maintaining their
differentiated state and impeding their reversion to a
stem-like state. Consistent with this hypothesis, depletion
of BAP1 caused a down-regulation of canonical genes of
the melanocyte differentiation program (MITF, TRPM1,
TYR and DCT) (Figure 6a). Similar changes were seen
in cultures of primary uveal melanocyte samples from
three independent patients stably expressing shRNA
against BAP1 or control shRNA against GFP and also
in two short-term cultures from fresh primary class 1
tumors (Figure 6a and data not shown). Further, stable
depletion of BAP1 in cultured primary uveal melanocytes
resulted in cells with fewer dendritic aborizations and
less differentiated spindle morphology, both of which
suggest melanocyte dedifferentiation (Figure 6b-c). In
addition, we saw consistent up-regulation of the stem
cell factor NANOG in BAP1-depleted uveal melanoma
cells (Figure 6d). OCT4 expression did not change with
BAP1 depletion, but this stem cell factor is tightly
maintained within a restricted range to avoid differenti-
ation [30].
To assess the capacity for self-replication, which is a
measure of “stemness”, BAP1-deficient and control cells
were flow sorted, single cells were seeded into separate
wells of low-attachment 96-well plates in serum-free
stem cell media, and the presence or absence of colonies
Figure 4 Loss of BAP1 does not promote growth of uveal melanoma in mouse flank and tail vein xenograft models. (a) Mouse xenograft
flank injections in which 1000 or 500 BAP1-deficient or control 92.1 or OCM1A stable cells, respectively were injected into the flanks of NSG mice.
(Left panel) 92.1 stable cells (Right panel) OCM1A stable cells. Tumor volume was measured at time of necropsy 64 days or 35 days after injection for
92.1 and OCM1A cells, respectively. (b) RNA expression levels of BAP1 in flank tumors formed from BAP1-deficient of control stable cell lines. RNA was
isolated at time of necropsy. Expression is shown as fold change compared to control shRNA cells (c-d) Mouse xenograft tail vein injections in which
10,000 BAP1-deficient or control 92.1 stable cells were injected into the tail veins of NSG mice. Necropsy was performed 29 days after injection and
liver metastasis was assessed (c) Representative cartoons of liver metastasis made from merged images of liver sections stained with H&E. Images were
merged using Adobe Photoshop. Normal liver tissue is shown in grey and metastases are in black. Original H&E merged images are shown in
Additional file 2. (d) Quantification of liver metastasis. Shown as the percent of tumor area compared to the total liver area. ImageJ software was used
to calculate area (e) Mouse xenograft tail vein injections in which 500,000 BAP1-deficient or control OCM1A stable cells were injected into the tail veins
of NSG mice. Liver and lung metastases were measured 30 days after injection. Metastases are shown as a percent of the total liver or lung area.
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from each well was assessed at 5 days. The BAP1-
deficient cells exhibited a 50% increased capacity for
self-replication compared to control cells (Figure 6e).
Further, whereas we showed earlier that BAP1-deficient
cells produced colonies in soft agar less efficiently than
control cells using our usual serum-containing culture
media (Figure 3c), the BAP1-deficient cells grew more
efficiently than control cells in the limiting stem cell
conditions of serum-free media and low attachment
plates (Figure 6f and Additional file 9).
As we showed previously, HDAC inhibition reverts
primary class 2 uveal melanoma cells to a differenti-
ated, less aggressive class 1 phenotype [16]. Consistent
with those results, treatment of BAP1-deficient uveal
melanoma cells with an HDAC inhibitor restored the
expression of the melanocyte differentiation markers,
which were down-regulated by BAP1 depletion, in a
dose-dependent manner (Figure 6g).
A major binding partner of BAP1 protein is the
transcriptional co-regulator HCF-1, which was recently
shown to play a key role in stem cell maintenance, in
part through regulation of RNA splicing [31]. As this
interaction has not been addressed within the me-
lanocytic lineage, we examined the interaction between
endogenous BAP1 and HCF-1 in BAP1-wildtype uveal
melanoma cells. Indeed, HCF-1 and BAP1 were found
to co-precipitate using antibodies against either protein
for immunoprecitapation, and approximately 75% of
total cellular BAP1 was in a complex with HCF-1
(Figure 7).
Discussion
In this report, we studied the effects of both transient
and stable RNAi-mediated depletion of BAP1 in uveal
melanoma cells. In agreement with previous work in
other cell types [11,13,27], transient BAP1 loss decreased
cell proliferation. However, we now show that this effect
is not sustained in cells that are stably depleted of BAP1,
implying that this initial growth defect is not a critical
factor in BAP1’s role as a tumor suppressor. Despite
variable levels in knockdown with the different siRNAs
and shRNAs used, we saw no correlation between the
level of expression and the degree of proliferation defect.
Surprisingly, stable loss of BAP1 had minimal or even
paradoxical effects in most standard assays of tumori-
genicity, including cell cycle control, motility and the
ability to form colonies in soft agar, suggesting that BAP1
loss promotes tumor progression in a manner that is
different from most characterized tumor suppressors.
The most striking effect of BAP1 loss was the induc-
tion of a primitive, stem-like phenotype characterized by
a loss of morphologic differentiation, down-regulation of
the melanocyte transcriptional program, up-regulation
of genes enriched in stem cells and developmental pro-
cesses, and enhanced growth capacity under stem cell
conditions. These findings are consistent with our previ-
ous findings in class 2 primary uveal melanomas in vivo
[32], and they implicate BAP1 in the maintenance of cell
identity in uveal melanoma.
Our findings are also in agreement with other recent
work on BAP1 function. BAP1 is a component of the
Figure 5 Gene expression profiling reveals altered RNA metabolism and developmental transcriptomic signatures in BAP1-deficient
uveal melanoma cells. (a) Gene expression heatmap generated in Partek of significantly altered genes (P < 0.01) in BAP1-deficient stable cells
compared to control stable cells after 4 weeks of shRNA expression. (b) The top six gene ontology categories represented by the significantly
changing genes in BAP1-deficient cells. Significant Analysis of Microarrays (SAM) was performed and a cutoff of q < 10% was used to determine
the most highly significant genes. Three of the genes in the ubiquitin system category are deubiquitinases (DUBs). (c) The top nine categories
represented after gene set enrichment analysis (GSEA) of BAP1-deficient cells using a threshold of P < 0.005. GSEA was performed using a
pre-ranked file generated after SAM analysis.
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Figure 6 Loss of BAP1 induces a dedifferentiated, stem-like phenotype in uveal melanoma cells. (a) RNA expression of melanocyte
differentiation markers in BAP1-deficient or control 92.1 stable cells, primary melanocytes, and primary class 1 tumor cells. Fold change is
compared to control knockdown cells. (b) Cell morphology of BAP1-deficient or control primary uveal melanocytes. (Left panel) representative
pictures. (Right panel) dendritic arborizations measured as the number of branch points per cell, with a bipolar cell having zero aborizations;
shown as percent of total cells. (c) Cell spindle morphology of BAP1-deficient or control primary uveal melanocytes after four weeks of shRNA
expression, measured as the ratio of cell length to cell width. (d) RNA expression levels of stem cell genes NANOG and OCT4 in BAP1-deficient or
control 92.1 and OCM1A stable cells. Fold change is compared to control knockdown cells. (e) Clonogenic assay using BAP1-deficient or control
OCM1A stable cells. One cell/well was grown in serum-free stem cell media in non-adherent 96-well plates. The number of wells producing
colonies was measured after 5 days. Data is shown as fold change over control. (f) Assay measuring the ability of BAP1-deficient or control stable
cells to grow in stem cell culture conditions on non-adherent plates in serum-free media. Colony size was measured after 5 (OCM1A) or 7 (92.1)
days using ImageJ software. (g) RNA expression of melanocyte differentiation markers in BAP1-deficient 92.1 stable cells after 72 hr treatment
with 0.5 mM, 1.0 mM, or 2.0 mM HDAC inhibitor (HDACi) as indicated. Fold change is compared to control knockdown cells.
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PR-DUB Polycomb repressive complex, which catalyzes
the removal of monoubiquitin moieties from H2A in
opposition to the ubiquitinating activity of the PRC1
complex that contains BMI1 [14]. We recently showed
that HDAC inhibitors, which block BMI1, revert primary
class 2 uveal melanoma cells to a differentiated class 1
phenotype. We now go on to show that HDAC inhibi-
tors restore to normal levels the expression of melano-
cyte differentiation genes that are down-regulated by
BAP1 depletion. Our work suggests that BAP1 activity is
important for maintaining melanocytic cell identity.
The transcriptional co-regulator HCF-1 is a major
binding partner of BAP1 and may regulate the genomic
localization of BAP1 through a multi-protein interaction
with the transcription factor YY1 [12,13] or, as shown
more recently, through interactions with OGT and
FOXK1/2 [17]. HCF-1 has traditionally been thought of
as a cell cycle regulator, but it now appears that the
complexes in which HCF-1 is found while regulating
the cell cycle may be distinct from those in which
BAP1 is found [17]. HCF-1 plays a key role in stem cell
maintenance, at least in part by regulating genes in-
volved in RNA splicing [31], and we showed here that
HCF-1 is the predominant BAP1 binding partner in
uveal melanoma cells, and that genes regulated by
BAP1 are enriched for those involved in cell cycle con-
trol and RNA splicing and processing. Further work is
needed to clarify the precise mechanism of action of
BAP1 and HCF-1 in tumor suppression, which may
vary depending on context and cell type.
Gene Set Enrichment Analysis of transcripts that were
deregulated in cells depleted of BAP1 revealed enrich-
ment of gene sets associated with metastasis in melan-
oma, prostate, lung, and pancreatic cancer, suggesting a
more general role for BAP1 loss in cancer progression.
These transcripts were also enriched in gene sets related
to the ubiquitin system, including both proteasomal and
chromatin remodeling components. This is consistent
with a growing body of work showing that these two
components of the ubiquitin system are in a dynamic
equilibrium that balances a rate-limiting pool of free ubi-
quitin [33]. These genes were also enriched in 6 DNA
damage/telomere maintenance gene sets and in 3 gene
sets that were specifically related to the BRCA1/2 path-
way. This is consistent with previous work linking BAP1
to BRCA1 [10]. However, the fact that BRCA1 was not
identified as a BAP1-interacting protein in several un-
biased screens in different cell types [12,18] indicates
that the cellular context in which this interaction may be
relevant remains unclear. One possibility is that BRCA1
and BAP1 interact specifically in the setting of DNA
damage repair, where H2A is monoubiquitinated by
BMI1, and BRCA1 is recruited to DNA lesions [34,35].
In any event, it is likely that the effects of BAP1 loss are
likely to be cell type-specific and context-dependent.
The precise mechanism by which the loss of cell iden-
tity induced by BAP1 loss leads to metastasis remains
unclear. The fact that BAP1-depleted uveal melanoma
cells did not exhibit a growth advantage or increased
metastatic capacity in xenograft mouse models was sur-
prising but indicates that these models are not adequate
for elucidating the role of BAP1 in vivo. One possibility
is that the genetic and/or epigenetic mechanisms that
prevent uveal melanocytes, which are derived from the
migratory cranial neural crest, from migrating away from
the eye may be disrupted by the loss of cell identity. If
this were the case and the critical event triggered by
BAP1 loss was the escape of tumor cells from the eye,
then our available xenograft models may be insufficient
to model this. Further investigation of this issue will
Figure 7 Physical interaction between BAP1 and HCF-1 in uveal melanoma cells. Immunoprecipitations (IP) for endogenous BAP1 and
HCF-1 from the combined lysates of UM cell lines. Westerns were performed on IP material and lysate supernatant that was collected after the IP
(cleared lysates). α-tubulin was used as a loading control for the cleared lysate samples only. Densitometry was performed using ImageJ and
showed ~75% of the total BAP1 was complexed with HCF-1. * denotes P < 0.05 and ** denotes P < 0.01 based on Student’s t-test.
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await the availability of genetically engineered animals
models.
Conclusions
In summary, we demonstrate that BAP1 is necessary for
maintenance of melanocyte identity in uveal melanoma
cells, and that loss of BAP1 leads to a loss of cell identity
and acquisition of a primitive, stem-like phenotype. This
effect is very similar to overexpression of the BAP1 antag-
onist, BMI1 in many forms of cancer [15] and points out
the vital role of histone ubiquitination and Polycomb-
mediated chromatin remodeling in cancer progression.
Therapeutic strategies that target these pathways are ur-
gently needed.
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reverse primer sequences used in all qPCR reactions performed.
Additional file 2: Original H&E images of liver metastases. The
original merged H&E images of liver metastases after tail vein injection of
92.1 BAP1-deficient and control cells.
Additional file 3: SAM analysis of gene expression profile results.
Significant Analysis of Microarrays results showing genes that were up or
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results.
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Figure 5c.
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the top gene sets significantly enriched in BAP1-deficient cells based on
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were performed on three uveal melanoma cell lines (OCM1A, 92.1 and
Mel290) expressing either BAP1 or control shRNA for four weeks.
Additional file 9: Representative images and MTS of stable cells in
stem cell conditions. (Left panels) Representative images of control and
BAP1-deficient 92.1 stable cells after culture for 7 days in stem cell media
in low attachment plates. (Right panel) MTS assay of control and
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